Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420468 | 0.83 | MEN1 (0.58) | MEN1MAPK1KMT2AEPHX2HSD11B1 | |
| SCHEMBL136224 | 0.82 | KMT2A (0.73) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL12699332 | 0.82 | MEN1 (0.57) | MEN1MAPK1KMT2AEPHX2HSD11B1 | |
| SCHEMBL13834441 | 0.81 | KMT2A (0.68) | MEN1MAPK1KMT2AEPHX2HSD11B1 | |
| SCHEMBL13968197 | 0.81 | MEN1 (0.59) | MEN1MAPK1KMT2AEPHX2HSD11B1 | |
| SCHEMBL13968196 | 0.81 | MEN1 (0.59) | MEN1MAPK1KMT2AEPHX2HSD11B1 | |
| SCHEMBL12759016 | 0.80 | EPHX1 (0.46) | KMT2AEPHX2HSD11B1EPHX1 | |
| SCHEMBL12832467 | 0.80 | EPHX1 (0.46) | KMT2AEPHX2HSD11B1EPHX1 | |
| SCHEMBL13968194 | 0.80 | MEN1 (0.58) | MEN1MAPK1KMT2AEPHX2HSD11B1 | |
| SCHEMBL17586286 | 0.79 | MEN1 (0.63) | MEN1MAPK1KMT2AEPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | MEN1 2430/4885MAPK1 2826/4885KMT2A 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.